What You Should Know about Used Cars and Open Recalls
It may surprise you.
In May 2019, a class-action lawsuit was filed against Boehringer Ingelheim Pharmaceuticals for allegedly deceptively marketing that the Combivent Respimat asthma inhaler will provide 120 doses when, according to plaintiffs, the inhaler contains far fewer dosages, sometimes less than half the advertised amount. (Ignacuinos et al v. Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-672, D. Conn.)
It may surprise you.
Verdict comes nine years after TINA.org alerted regulator to supplement’s unsubstantiated health claims.
Regulators have a beef with company’s climate pledge.
Consumers need to be wary of undisclosed incentivized reviews.
Why TINA.org supports FTC’s proposed changes to COPPA Rule but pushes for more.